IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status

Christiansen, Jens Sandahl; Home, Philip; Kumar, Ajay

doi:10.1586/17446651.2016.1145541

Cited by 4 publications

(4 citation statements)

References 45 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The formation of stable dihexamers in formulation also offers the potential for IDeg U100 to be co‐formulated with the rapid‐acting analogue insulin aspart without hybrid hexamers forming, or with liraglutide, a glucagon‐like peptide‐1 receptor agonist. The clinical utility of these fixed‐combination products has been demonstrated in several cohorts of patients with type 2 diabetes …”

Section: Multihexamer Chain Formation: Insulin Degludecmentioning

confidence: 99%

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Heise

Mathieu

2016

Diabetes Obesity Metabolism

105

View full text Add to dashboard Cite

Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction have been used in pursuit of a basal insulin, for which a low injection frequency would provide tolerable and reproducible glucose control; these mechanisms have met with varying degrees of success. Before the advent of recombinant DNA technology, development focused on modifications to the formulation that increased insulin self‐association, such as supplementation with zinc or the development of preformed precipitates using protamine. Indeed, NPH insulin remains widely used today despite a frequent need for a twice‐daily dosing and a relatively high incidence of hypoglycaemia. The early insulin analogues used post‐injection precipitation (insulin glargine U100) or dimerization and albumin binding (insulin detemir) as methods of increasing therapeutic duration. These products approached a 24‐hour glucose‐lowering effect with decreased variability in insulin action. Newer basal insulin analogues have used up‐concentration in addition to precipitation (insulin glargine U300), and multihexamer formation in addition to albumin binding (insulin degludec), to further increase duration of action and/or decrease the day‐to‐day variability of the glucose‐lowering profile. Clinically, the major advantage of these recent analogues has been a reduction in hypoglycaemia with similar glycated haemoglobin control when compared with earlier products. Future therapies may bring clinical benefits through hepato‐preferential insulin receptor binding or very long durations of action, perhaps enabling once‐weekly administration and the potential for further clinical benefits.

show abstract

Section: Multihexamer Chain Formation: Insulin Degludecmentioning

confidence: 99%

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Heise

Mathieu

2016

Diabetes Obesity Metabolism

105

View full text Add to dashboard Cite

show abstract

“…Insulin degludec/insulin aspart (IDegAsp; Ryzodeg ® ) is a novel co-formulation of 70% IDeg and 30% insulin aspart (IAsp, a rapid-acting insulin) administered as a single injection, either once or twice daily with main meals [ 2 ], wherein each insulin exerts its glucose-lowering effects without establishing interactions with the other agents [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or basal insulin. We extracted data from citation databases, including PubMed, EMBASE, and the Cochrane Library, since inception to 2021. We calculated the mean differences for hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), self-measured mean glucose, and postprandial glucose (PPG) and odds ratios for confirmed hypoglycemia events. Compared with twice-daily conventional premixed insulin, twice-daily IDegAsp showed a similar effect on changes in HbA1c, but it significantly reduced FPG and self-measured mean glucose levels. Furthermore, compared to once-daily basal insulin, once-daily IDegAsp had a similar effect on changes in HbA1c, but it significantly reduced self-measured mean glucose and PPG levels. The risk of overall confirmed hypoglycemia was similar between treatments; however, the risk of nocturnal hypoglycemia events was significantly lower with IDegAsp than with conventional premixed insulin and basal insulin. Thus, IDegAsp was more effective than conventional premixed insulin and basal insulin at reducing blood glucose with fewer nocturnal hypoglycemia events.

show abstract

“…IDeg/Asp both has the characteristics of long-acting insulin and fast-acting insulin. Studies have found that compared with IGlar, IDeg/Asp could better control blood glucose and reduce the frequency of hypoglycemia events [10,18,22], but there have been few reports comparing efficacy and safety between IDeg/Asp and IGlar. Therefore, we conducted a meta-analysis of trials to evaluate and compare the efficacy and safety of IDeg/Asp and IGlar in the treatment of T2DM to provide a more beneficial comprehending and planning for clinical decision-making and future studies.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, compared with insulin degludec/aspart (IDeg/Asp), insulin glargine (IGlar) is associated with a potential risk of hypoglycemia. IDeg/Asp combines IDeg and IAsp (7:3), which provides effective glycemic control, reduces hypoglycemia rate (particularly nocturnal hypoglycemia), allows a flexible injection time [10]. As the first coformulation of long-acting and short-acting insulin, IDeg/Asp retains its unique pharmacokinetic (PK) /pharmacodynamic (PD) properties [11].…”

mentioning

confidence: 99%

Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials

Long

Lin

et al. 2022

Endocr J

View full text Add to dashboard Cite

Recent studies have found compared with insulin glargine (IGlar), insulin degludec/aspart (IDeg/Asp) may provide adequate glycemic control and prevent hypoglycemia events in type 2 diabetes mellitus (T2DM). Consequently, we performed a meta-analysis to appraise and compare the efficiency and safety of IDeg/Asp and IGlar in the treatment of T2DM. We sought the databases including PubMed, Embase, Scopus, Cochrane library to confirm related articles which inspected the effect of IDeg/Asp versus IGlar for the treatment of T2DM until May 2021. Finally, six randomized controlled trials (RCTs) of 1,346 patients were included. The results showed that IDeg/Asp significantly decreased the mean hemoglobin A1c (HbA1c) level but was prone to serious adverse events, and IGlar increased the nocturnal confirmed hypoglycemia events. Besides, there were no significant changes in other indicators, including mean fasting plasma glucose (FPG) level, nine-point self-measured plasma glucose (SMPG) level, and adverse events. What's more, we found that there was no significant difference in the occurrence of hypoglycemia overall, but our subgroup analysis of confirmed hypoglycemia revealed the population in this subgroup (duration of diabetes ≤11 years) might has its particularity effecting the hypoglycemia outcome. Concerning efficiency, IDeg/Asp may have advantages in controlling the mean HbA1c level. Regarding safety, IGlar might increase the risk of nocturnal confirmed hypoglycemia. Further evidence is needed to compare better the efficiency and safety of IDeg/Asp versus IGlar therapy.

show abstract

IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status

Cited by 4 publications

References 45 publications

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis

Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About